BARCELONA, Jan 19 (Reuters) - Spanish biopharmaceutical company Grifols GRF.MC expects 2006 sales to grow 22 percent to 640 million euros ($829 million), and sees growth accelerating in the second half of 2007, a company official has said. Barcelona-based Grifols, which floated on the Spanish stock exchange in May, derives products from blood for hospital uses like clinical nutrition and recently got U.S. marketing approval for its blood derivative product, Flebogamma.
“This growth tendency will intensify from the second half of 2007 due to the impact of sales of Flebogamma,” Nuria Pascual, head of investor relations said in an interview with Reuters/EP late on Thursday.
Grifols hopes to get European marketing rights for Flebogamma in early 2008, Pascual said.
Shares in Grifols, which have risen over a third since the beginning of December, were trading 1.7 percent higher at 11.3 euros by 1057 GMT.
((Reporting by Reuters/EP; Writing by Sonya Dowsett; editing by Paul Bolding; Reuters Messaging: firstname.lastname@example.org; 34 91 585 8328))
($1=.7719 Euro) Keywords: HEALTH GRIFOLS/
C Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nL19339326